Goswami Dibakar, Machini M Teresa, Silvestre Daniel M, Nomura Cassiana S, Esposito Breno Pannia
Departamentos de Química Fundamental e de ‡Bioquímica, Instituto de Química, Universidade de São Paulo , Av. Lineu Prestes 748, 05508-000, São Paulo, Brazil.
Bioconjug Chem. 2014 Nov 19;25(11):2067-80. doi: 10.1021/bc5004197. Epub 2014 Oct 20.
Iron overload causes progressive and sometimes irreversible damage due to accelerated production of reactive oxygen species. Desferrioxamine (DFO), a siderophore, has been used clinically to remove excess iron. However, the applications of DFO are limited because of its inability to access intracellular labile iron. Cell penetrating peptides (CPPs) have become an efficient delivery vector for the enhanced internalization of drugs into the cytosol. We describe, herein, an efficient method for covalently conjugating DFO to the CPPs TAT(47-57) and Penetratin. Both conjugates suppressed the redox activity of labile plasma iron in buffered solutions and in iron-overloaded sera. Enhanced access to intracellular labile iron compared to the parent siderophore was achieved in HeLa and RBE4 (a model of blood-brain-barrier) cell lines. Iron complexes of both conjugates also had better permeability in both cell models. DFO antioxidant and iron binding properties were preserved and its bioavailability was increased upon CPP conjugation, which opens new therapeutic possibilities for neurodegenerative processes associated with brain iron overload.
铁过载由于活性氧物种的加速产生会导致进行性且有时不可逆的损伤。去铁胺(DFO),一种铁载体,已在临床上用于去除过量的铁。然而,DFO的应用受到限制,因为它无法进入细胞内不稳定铁。细胞穿透肽(CPPs)已成为一种有效的递送载体,可增强药物内化进入细胞质。在此,我们描述了一种将DFO与CPPs TAT(47 - 57)和穿膜肽共价偶联的有效方法。两种偶联物在缓冲溶液和铁过载血清中均抑制了不稳定血浆铁的氧化还原活性。与母体铁载体相比,在HeLa和RBE4(血脑屏障模型)细胞系中实现了对细胞内不稳定铁的更好摄取。两种偶联物的铁络合物在两种细胞模型中也具有更好的通透性。DFO的抗氧化和铁结合特性得以保留,并且其生物利用度在与CPP偶联后增加,这为与脑铁过载相关的神经退行性过程开辟了新的治疗可能性。